RZLTHealthcare · BiotechnologyRZLT Stock Forecast: Rezolute, Inc. Price Predictions for 2026-2027
The 10 Wall Street analysts covering Rezolute, Inc. hold a median 12-month price target of $6 — +30.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
RZLT stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Rezolute, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (56): Smaller than most of the companies we track.
Quality (32): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
RZLT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RZLT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +30.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 June 2026 | Guggenheim | Maintains | Buy | $6.00 → $11 |
| 3 June 2026 | Citizens | Upgrade | Market Outperform | — |
| 3 June 2026 | Maxim Group | Maintains | Buy | — |
| 3 June 2026 | Wedbush | Maintains | Outperform | — |
| 2 June 2026 | BTIG | Maintains | Buy | — |
| 2 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2026 | Maxim Group | Maintains | Buy | — |
| 25 Mar 2026 | Wedbush | Upgrade | Outperform | — |
| 8 Jan 2026 | BTIG | Reiterates | Buy | — |
| 8 Jan 2026 | Wedbush | Maintains | Neutral | — |
| 12 Dec 2025 | Guggenheim | Maintains | Buy | — |
| 12 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Nov 2025 | BTIG | Reiterates | Buy | — |
| 29 Oct 2025 | Citizens | Maintains | Market Outperform | — |
| 22 Sept 2025 | Guggenheim | Reiterates | Buy | — |
| 19 Sept 2025 | Maxim Group | Maintains | Buy | — |
| 18 Sept 2025 | BTIG | Reiterates | Buy | — |
| 3 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RZLT appears on the weeks it earns a place.
RZLT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Rezolute, Inc. (RZLT) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −4.7×
- Price / sales
- —
- Price / book
- 4.1×
- EV / EBITDA
- −3.8×
Cheaper than 89% of US stocks
Cheaper than 27% of US stocks
Cheaper than 76% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −81.7%
- Return on assets
- −48.7%
- Dividend yield
- —
Higher than 15% of US stocks
Higher than 8% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
RZLT vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Rezolute, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about RZLT stock
What is the RZLT stock price forecast for 2026-2027?
The 10 Wall Street analysts covering Rezolute, Inc. have a median 12-month price target of $6, with estimates ranging from $4 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RZLT stock a buy right now?
Of the 10 analysts covering Rezolute, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rezolute, Inc. 34 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RZLT?
As at 15 Aug 2026, Rezolute, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (56 of 100).
Will RZLT stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts implies +30.4% from the last close, and Ticker Nerd's factor model ranks Rezolute, Inc. 34 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RZLT stock forecast for 2030?
No analyst covering Rezolute, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RZLT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $14 over the next 12 months.
How has RZLT stock performed over the past year?
Rezolute, Inc. returned -28.8% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Rezolute, Inc. do?
Rezolute, Inc. is a late-stage rare disease company focused on developing therapies to improve outcomes for individuals with hypoglycemia caused by hyperinsulinism, including congenital and tumor forms.
About Rezolute, Inc.
Rezolute, Inc. is a late-stage rare disease company focused on developing therapies to improve outcomes for individuals with hypoglycemia caused by hyperinsulinism, including congenital and tumor forms. Its lead clinical asset, ersodetug, is an intravenously administered human monoclonal antibody that binds to an allosteric site on the insulin receptor in target tissues like the liver, fat, and muscle. Ersodetug is in Phase 3 clinical trials for congenital hyperinsulinism, an ultra-rare pediatric genetic disorder characterized by excessive insulin production, and for tumor hyperinsulinism. The company is also advancing RZ402, an oral plasma kallikrein inhibitor designed for the chronic treatment of diabetic macular edema, a diabetes-related vascular complication leading to vision impairment by blocking bradykinin production to reduce vascular leakage and inflammation. Rezolute, Inc. operates in the biotechnology sector, targeting unmet needs in rare metabolic and ophthalmologic disorders. Founded in 2010 and headquartered in Redwood City, California, it emphasizes innovative antibody and small molecule therapies for severe, life-threatening conditions.
CEO Mr. Nevan Charles Elam J.D. · 68 employees · United States · https://www.rezolutebio.com